Sourav Kole
Director/Board Member at Paros Bio, Inc.
Profile
Sourav joined Dolby Family Ventures as Managing Director of Life Sciences in 2022, where he invests in early-stage neuro companies with particular focus on Alzheimer’s Disease and broadly neurodegeneration, clinical depression and broadly psychiatry, and neurotech.
Sourav is a board director of MindImmune Therapeutics and Reservoir Neuroscience and a board observer of Libra Therapeutics, Neurotherapia, Paros Bio, Quralis, and Therini.
Prior to Dolby Family Ventures, Sourav was at Verily (fka Google Life Sciences) as the business lead for programs and partnerships for a wide-range of next-generation technologies at the convergence of life sciences and data science.
This includes programs with Allergan, the Broad Institute, Gilead, Procter & Gamble, Verb Surgical (acquired by Johnson & Johnson) and Verily’s efforts towards the opioid epidemic and the COVID-19 pandemic (helping to test 2M+ people between March to July 2020).
Prior to Verily, Sourav was at Varian (previously, NYSE: VAR), where he enabled the strategic transformation of the company.
At Varian, Sourav created corporate strategy, executed towards that strategy via $2B of M&A, partnerships, and equity investments, cofounded a venture capital arm, grew the ~$250M China business while working in China, and led the rollup of interventional oncology assets to create a new business unit.
Varian was acquired by Siemens Healthineers for $16.4B.
Prior to Varian, Sourav built, consulted for, and invested in a number of early-stage healthcare companies.
Successful exits across his investing experiences include Arterys (acquired by Tempus), Fusion Pharma (NASDAQ: FUSN), Grail (acquired by Illumina), Health Catalyst (NASDAQ: HCAT), Instructure (NYSE: INST), Lineagen (acquired by Bionano Genomics), Lyft (NASDAQ: LYFT), Zebra Medical (acquired by Nanox).
Sourav Kole active positions
| Companies | Position | Start |
|---|---|---|
Paros Bio, Inc.
 Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | Director/Board Member | 2021-12-31 |
Dolby Family Ventures LLC
 Dolby Family Ventures LLC Investment ManagersFinance Dolby Family Ventures (Dolby) is a venture capital firm founded in 2013. The firm is headquartered in San Francisco, California. | Private Equity Investor | 2021-12-31 |
NeuroTherapia, Inc.
 NeuroTherapia, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapia, Inc. discovers and develops new therapies for diseases with an underlying component of neuroinflammation. The company was founded by Mohamed Naguib Attala and Joseph F. Foss in 2015 and is headquartered in Cleveland, OH. | Director/Board Member | 2021-12-31 |
Libra Therapeutics, Inc.
 Libra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Libra Therapeutics, Inc. operates as biotechnology company which develops novel disease-modifying therapeutics. It focuses on the areas of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company is headquartered in San Diego, CA. | Director/Board Member | 2021-12-31 |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Director/Board Member | 2021-12-31 |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Director/Board Member | 2021-12-31 |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA. | Director/Board Member | 2021-12-31 |
Mindimmune Therapeutics, Inc.
 Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mindimmune Therapeutics, Inc. develops drugs that target the immune system to treat diseases of the central nervous system. It focuses on the treatment of Alzheimer's, Huntington's disease, pain, and psychiatric disorders. The company was founded by Stevin Zorn, Frank S. Menniti, Robert B. Nelson, and Brian M. Campbell on July 12, 2016 and is headquartered in Kingston, RI. | Director/Board Member | 2021-12-31 |
Reservoir Neuroscience, Inc.
 Reservoir Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Reservoir Neuroscience, Inc. develops novel therapeutics. It focuses on treating dysfunctional blood vessels in the brain other neurological disorders. The company was founded by Aaron Friedman in 2019 and is headquartered in Berkeley, CA. | Director/Board Member | 2021-12-31 |
Former positions of Sourav Kole
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | Health Technology |
Dolby Family Ventures LLC
Dolby Family Ventures LLC Investment ManagersFinance Dolby Family Ventures (Dolby) is a venture capital firm founded in 2013. The firm is headquartered in San Francisco, California. | Finance |
NeuroTherapia, Inc.
NeuroTherapia, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapia, Inc. discovers and develops new therapies for diseases with an underlying component of neuroinflammation. The company was founded by Mohamed Naguib Attala and Joseph F. Foss in 2015 and is headquartered in Cleveland, OH. | Health Technology |
Libra Therapeutics, Inc.
Libra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Libra Therapeutics, Inc. operates as biotechnology company which develops novel disease-modifying therapeutics. It focuses on the areas of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company is headquartered in San Diego, CA. | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Health Technology |
Therini Bio, Inc.
Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA. | Commercial Services |
Mindimmune Therapeutics, Inc.
Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mindimmune Therapeutics, Inc. develops drugs that target the immune system to treat diseases of the central nervous system. It focuses on the treatment of Alzheimer's, Huntington's disease, pain, and psychiatric disorders. The company was founded by Stevin Zorn, Frank S. Menniti, Robert B. Nelson, and Brian M. Campbell on July 12, 2016 and is headquartered in Kingston, RI. | Health Technology |
Reservoir Neuroscience, Inc.
Reservoir Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Reservoir Neuroscience, Inc. develops novel therapeutics. It focuses on treating dysfunctional blood vessels in the brain other neurological disorders. The company was founded by Aaron Friedman in 2019 and is headquartered in Berkeley, CA. | Health Technology |
Xenocor, Inc.
 Xenocor, Inc. Medical SpecialtiesHealth Technology Xenocor, Inc. is a privately held corporation based in Utah that offers a suite of leading-edge, fog-free, disposable surgical technologies for minimally invasive, abdominal, and thoracic procedures. The American company also offers a suite of leading-edge, fog-free, single-use endoscopes for minimally invasive surgical procedures. These products emerged from the Center for Medical Innovation and are FDA cleared, CE marked, and patent protected. The company was founded by John Langell, Lane Brooks, and Sourav Kole, and the CEO is Evan Kelso. | Health Technology |
- Stock Market
- Insiders
- Sourav Kole
